Carboplatin

Carboplatin Kabi is a platinum based antineoplastic drug used in chemotherapy.

Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquations rates.

Strengths:

• Carboplatin (Kemocarb) 150 mg/15 ml
• Carboplatin (Kemocarb) 450 mg/45 ml

Note: Aluminum reacts with Carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of Carboplatin Injection.

Single-Agent Therapy

Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 IV on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of Carboplatin should not be repeated until 4 weeks after the previous course and/or until the neutrophil count is at least 2000 and the platelet count is at least 100,000.

Combination Therapy with Cyclophosphamide

In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of:

Carboplatin —300 mg/m2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing). Cyclophosphamide (600 mg/m2) IV on day 1 every 4 weeks for 6 cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert.

Intermittent courses of Carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.

Initial Treatment of Advanced Ovarian Carcinoma

KEMOCARB (Carboplatin Injection) is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin and cyclophosphamide.

Secondary Treatment of Advanced Ovarian Carcinoma

KEMOCARB (Carboplatin Injection) is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

Strengths:

Carboplatin (Kemocarb) 150 mg/15 ml

Carboplatin (Kemocarb) 450 mg/45 ml

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory